Tumour biological features of BRCA1-induced breast and ovarian cancer - PubMed (original) (raw)
Tumour biological features of BRCA1-induced breast and ovarian cancer
O T Jóhannsson et al. Eur J Cancer. 1997 Mar.
Abstract
BRCA1 mutations, although implicated in disease predisposition in a major part of the hereditary breast cancer population, do not seem to be crucially involved in tumorigenesis of sporadic breast and ovarian cancers. This suggests that tumours arising in BRCA1 mutation carriers may differ from BRCA1 negative hereditary and sporadic cancer in genetic and biological features, as well as in clinical behaviour. Prior to BRCA1 analysis, 79 breast and 19 ovarian tumours from 57 breast and breast-ovarian cancer families, and 170 tumours from a comparison group of stage II breast cancers were studied with regard to histopathological features; immunohistochemistry [c-erbB-2, p53, oestrogen receptor (ER) and progesterone receptor (PR)], DNA flow cytometry and S-phase fraction. BRCA1 mutations were found in 40 breast and 15 ovarian tumours. The BRCA1 positive breast tumours were significantly more often of ductal type, histological grade III and manifested a heavy lymphocyte infiltration. Additionally, as compared to BRCA1 negative tumours, the BRCA1 positive tumours were significantly more often ER, PgR and c-erbB-2 negative. Furthermore, they were significantly more often DNA non-diploid, as well as being characterised by higher S-phase fraction values. These results suggest that BRCA1-induced breast cancers may manifest distinct tumour biological features of clinical importance.
Similar articles
- Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.
van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH, van Diest PJ. van der Groep P, et al. J Clin Pathol. 2006 Jun;59(6):611-7. doi: 10.1136/jcp.2005.032151. Epub 2006 Apr 7. J Clin Pathol. 2006. PMID: 16603649 Free PMC article. - BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Borg A, Dørum A, Heimdal K, Maehle L, Hovig E, Møller P. Borg A, et al. Dis Markers. 1999 Oct;15(1-3):79-84. doi: 10.1155/1999/278269. Dis Markers. 1999. PMID: 10595257 Free PMC article. - Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.
Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H. Eerola H, et al. Breast Cancer Res. 2005;7(1):R93-100. doi: 10.1186/bcr953. Epub 2004 Nov 19. Breast Cancer Res. 2005. PMID: 15642173 Free PMC article. - Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P. Casey MJ, et al. Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861. Gynecol Oncol. 2000. PMID: 10985881 Review. - [Hereditary ovarian cancer].
Zikán M, Foretová L, Cibula D, Kotlas J, Pohlreich P. Zikán M, et al. Ceska Gynekol. 2006 May;71(3):246-51. Ceska Gynekol. 2006. PMID: 16768054 Review. Czech.
Cited by
- Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.
Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT. Liu X, et al. NPJ Breast Cancer. 2022 May 10;8(1):64. doi: 10.1038/s41523-022-00427-9. NPJ Breast Cancer. 2022. PMID: 35538088 Free PMC article. - Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients.
Kim EK, Park SY, Kim SW. Kim EK, et al. J Pathol Transl Med. 2020 Jul;54(4):265-275. doi: 10.4132/jptm.2020.04.07. Epub 2020 May 14. J Pathol Transl Med. 2020. PMID: 32397691 Free PMC article. Review. - Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Hussein IA, Ahmed ST, Hameedi AD, Naji RZ, Alharbawi L, Alkhaytt M, Pity IS. Hussein IA, et al. Asian Pac J Cancer Prev. 2020 Apr 1;21(4):1025-1029. doi: 10.31557/APJCP.2020.21.4.1025. Asian Pac J Cancer Prev. 2020. PMID: 32334465 Free PMC article. - Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.
Scott CM, Wong EM, Joo JE, Dugué PA, Jung CH, O'Callaghan N, Dowty J, Giles GG, Hopper JL, Southey MC. Scott CM, et al. Exp Mol Pathol. 2018 Dec;105(3):404-410. doi: 10.1016/j.yexmp.2018.11.006. Epub 2018 Nov 10. Exp Mol Pathol. 2018. PMID: 30423315 Free PMC article. - BRCA1 Promoter Methylation and Clinicopathological Characteristics in Sporadic Breast Cancer Patients in Indonesia.
Harahap WA, Sudji IR, Nindrea RD. Harahap WA, et al. Asian Pac J Cancer Prev. 2018 Sep 26;19(9):2643-2649. doi: 10.22034/APJCP.2018.19.9.2643. Asian Pac J Cancer Prev. 2018. PMID: 30256562 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous